Salvage Therapy and Allogeneic Hematopoietic Cell Transplantation for the Severe Cytokine Storm Syndrome of Hemophagocytic Lymphohistiocytosis

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2024 Aug 8

PMID 39117843

Authors

Rebecca A Marsh

Affiliations

Soon will be listed here.

Abstract

Hemophagocytic lymphohistiocytosis (HLH) can be considered as a severe cytokine storm syndrome disorder. HLH typically manifests as a life-threatening inflammatory syndrome characterized by fevers, cytopenias, hepatosplenomegaly, and various other accompanying manifestations such as coagulopathy, hepatitis or liver failure, seizures or altered mental status, and even multi-organ failure. Standard up-front treatments do not always bring HLH into remission or maintain adequate response, and salvage or alternative therapies are often needed. For patients with genetic diseases that cause HLH, curative allogeneic hematopoietic cell transplantation is usually offered to prevent future episodes of life-threatening HLH. Here, we will discuss the options and approaches for salvage therapy and hematopoietic cell transplantation for patients with HLH.

References

Henter J, Arico M, Egeler R, Elinder G, Filipovich A, Gadner H . Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002; 100(7):2367-73. DOI: 10.1182/blood-2002-01-0172. View

Henter J, Horne A, Arico M, Egeler R, Filipovich A, Imashuku S . HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2006; 48(2):124-31. DOI: 10.1002/pbc.21039. View

Ammann S, Lehmberg K, Zur Stadt U, Janka G, Rensing-Ehl A, Klemann C . Primary and secondary hemophagocytic lymphohistiocytosis have different patterns of T-cell activation, differentiation and repertoire. Eur J Immunol. 2016; 47(2):364-373. PMC: 7163530. DOI: 10.1002/eji.201646686. View

Stepp S, Le Deist F, Bhawan S, Certain S, Mathew P, Henter J . Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999; 286(5446):1957-9. DOI: 10.1126/science.286.5446.1957. View

Feldmann J, Callebaut I, Raposo G, Certain S, Bacq D, Dumont C . Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003; 115(4):461-73. DOI: 10.1016/s0092-8674(03)00855-9. View

Zur Stadt U, Schmidt S, Kasper B, Beutel K, Diler A, Henter J . Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet. 2005; 14(6):827-34. DOI: 10.1093/hmg/ddi076. View

Zur Stadt U, Rohr J, Seifert W, Koch F, Grieve S, Pagel J . Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am J Hum Genet. 2009; 85(4):482-92. PMC: 2756548. DOI: 10.1016/j.ajhg.2009.09.005. View

Menasche G, Pastural E, Feldmann J, Certain S, Ersoy F, Dupuis S . Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet. 2000; 25(2):173-6. DOI: 10.1038/76024. View

Nagle D, Karim M, Woolf E, Holmgren L, Bork P, Misumi D . Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat Genet. 1996; 14(3):307-11. DOI: 10.1038/ng1196-307. View

10.

Coffey A, Brooksbank R, Brandau O, Oohashi T, Howell G, Bye J . Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 1998; 20(2):129-35. DOI: 10.1038/2424. View

11.

Nichols K, Harkin D, Levitz S, Krainer M, Kolquist K, Genovese C . Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 1998; 95(23):13765-70. PMC: 24894. DOI: 10.1073/pnas.95.23.13765. View

12.

Sayos J, Wu C, Morra M, Wang N, Zhang X, Allen D . The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 1998; 395(6701):462-9. DOI: 10.1038/26683. View

13.

Rigaud S, Fondaneche M, Lambert N, Pasquier B, Mateo V, Soulas P . XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature. 2006; 444(7115):110-4. DOI: 10.1038/nature05257. View

14.

Cannons J, Tangye S, Schwartzberg P . SLAM family receptors and SAP adaptors in immunity. Annu Rev Immunol. 2011; 29:665-705. DOI: 10.1146/annurev-immunol-030409-101302. View

15.

Nichols K, Hom J, Gong S, Ganguly A, Ma C, Cannons J . Regulation of NKT cell development by SAP, the protein defective in XLP. Nat Med. 2005; 11(3):340-5. PMC: 10655637. DOI: 10.1038/nm1189. View

16.

Pasquier B, Yin L, Fondaneche M, Relouzat F, Bloch-Queyrat C, Lambert N . Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J Exp Med. 2005; 201(5):695-701. PMC: 2212840. DOI: 10.1084/jem.20042432. View

17.

Snow A, Marsh R, Krummey S, Roehrs P, Young L, Zhang K . Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. J Clin Invest. 2009; 119(10):2976-89. PMC: 2752081. DOI: 10.1172/JCI39518. View

18.

Damgaard R, Fiil B, Speckmann C, Yabal M, Zur Stadt U, Bekker-Jensen S . Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling. EMBO Mol Med. 2013; 5(8):1278-95. PMC: 3944466. DOI: 10.1002/emmm.201303090. View

19.

Damgaard R, Nachbur U, Yabal M, Wong W, Fiil B, Kastirr M . The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol Cell. 2012; 46(6):746-58. DOI: 10.1016/j.molcel.2012.04.014. View

20.

Yabal M, Muller N, Adler H, Knies N, Gross C, Damgaard R . XIAP restricts TNF- and RIP3-dependent cell death and inflammasome activation. Cell Rep. 2014; 7(6):1796-808. DOI: 10.1016/j.celrep.2014.05.008. View